| Objective:By observing the effect of Yangyin Bufei Jiedu formula combined with platinum containing first-line chemotherapy on the clinical syndrome,quality of life,physical condition,tumor focus size,tumor markers and side effects of patients with Qi Yin deficiency of advanced non-small cell lung cancer,to evaluate the role of Yangyin Bufei Jiedu formula in the treatment of advanced non-small cell lung cancer,so as to expand the clinical application of Yangyin Bufei Jiedu formula in lung cancer The scope of application in the treatment.Methods:From April 2019 to March 2020,60 patients with advanced NSCLC were admitted to Jiangsu integrated hospital of traditional Chinese and Western medicine.They were randomly divided into two groups,30 cases in the control group(the first-line chemotherapy with platinum only)and 30 cases in the treatment group(Yangyin Bufei Jiedu formula combined with platinum containing first-line chemotherapy).21 days is a treatment cycle,two cycles in a row.After the control group communicates with the patients and their families,the individualized chemotherapy scheme is selected.The treatment group adjusts the medication on the basis of Nourishing Yin,nourishing lung and detoxifying formula,and decreases with the symptoms.Before and after treatment,the clinical symptoms,behavior state,quality of life,solid tumor and tumor index were observed.Results:1.TCM syndrome efficacy comparison:in the treatment group,30 patients showed significant effect in 1 case,effective in 18 cases,ineffective in 11 cases,effective in 63.3%;in the control group,30 patients showed significant effect in 0 cases,effective in 3 cases,ineffective in 27 cases,effective in 10%.There was significant difference between the two groups(P<0.01).2.Comparison of physical strength score:before treatment,the KPS score of the treatment group was 72.33±9.71,and that of the control group was 71.67±10.20,with no statistical difference between the two groups;after treatment,the KPS score of the treatment group was 85.00±13.83,and that of the control group was 76.67±17.29,with statistical difference between the two groups(P<0.05).3.Comparison of quality of life:there was statistical difference between the treatment group and the control group in general health and fatigue,nausea and vomiting,diarrhea symptoms(P<0.05),there were significant differences in general health,fatigue and diarrhea between the two groups(P<0.01).4.Recent objective curative effect comparison:in the treatment group,no patient was completely relieved,12 patients were partially relieved,16 patients were stable,2 patients were progressive,the disease control rate was 93.33%,the effective rate was 40.00%;in the control group,no patient was completely relieved,8 patients were partially relieved,18 patients were stable,4 patients were progressive,the disease control rate was 86.67%,and the effective rate was 26.67%.The control rate and effective rate in the treatment group were higher than those in the control group,but there was no statistical difference between the two groups(P>0.05).5.Comparison of tumor markers:CEA in the treatment group decreased from(18.64±11.83)to(13.12±10.95),with a statistically significant difference(P<0.01);CEA in the control group decreased from(17.02±13.13)to(14.27±12.18),with a statistically significant difference(P<0.01).CA125 in the treatment group decreased from(30.61±15.62)to(21.64±10.57),with a statistically significant difference(P<0.01);CA125 in the control group decreased from(27.92±14.39)to(24.71±12.99),with a statistically significant difference(P<0.01).CA199 in the treatment group decreased from(24.15±14.14)to(17.14±10.84),with a statistically significant difference(P<0.01);CA199 in the control group decreased from(22.26±13.90)to(19.58±13.11),with a statistically significant difference(P<0.01).However,there was no significant difference in CEA,CA125 and CA199 between the two groups after treatment(P>0.05).6.Comparison of immune function:the percentage of NK cells and CD4+/CD8+ in the treatment group were relatively stable before and after treatment,without statistical difference(P>0.05);the percentage of NK cells and CD4+/CD8+ in the control group decreased significantly before and after treatment(P<0.01);there was no statistical difference between the two groups after treatment(P>0.05).7.Weight comparison:after treatment,13 cases of weight gain,14 cases of stability and 3 cases of reduction in the treatment group,with an effective rate of 90.0%;after treatment,10 cases of weight gain,13 cases of stability and 7 cases of reduction in the control group,with an effective rate of 76.7%.The effective rate of the treatment group was higher than that of the control group,but there was no statistical difference by kruskar Wallis test(P>0.05).8.Adverse reactions comparison:there was significant difference between the treatment group and the control group in preventing leucopenia and alleviating gastrointestinal nausea,vomiting and diarrhea(P<0.05).Conclusions:Yangyin Bufei Jiedu formula combined with platinum containing first-line chemotherapy can alleviate the clinical symptoms of patients with advanced non-small cell lung cancer with deficiency of both qi and Yin,improve the quality of life and physical condition of the patients,and the side effects are relatively mild. |
PDF Full Text Request